胃复春片联合艾司奥美拉唑镁肠溶片治疗脾胃虚弱型十二指肠球部溃疡的临床效果
|
摘要
目的探究胃复春片联合艾司奥美拉唑镁肠溶片治疗脾胃虚弱型十二指肠球部溃疡的效果。方法选取2016年9月～2018年2月我院收治的100例脾胃虚弱型十二指肠球部溃疡患者作为研究对象,按照随机数字表法将其分成治疗1组(50例)与治疗2组(50例)。治疗1组患者采用胃复春片联合艾司奥美拉唑镁肠溶片治疗,治疗2组患者采用艾司奥美拉唑镁肠溶片治疗。比较两组患者的治疗效果、腹痛及溃疡消失时间、视觉模拟评分(VAS)、日常生活能力(ADL)评分、不良反应发生情况。结果治疗1组患者的治疗总有效率为98.00%,高于治疗2组的86.00%,差异有统计学意义(P<0.05)。治疗1组患者的腹痛、溃疡消失时间短于治疗2组,差异有统计学意义(P<0.05)。治疗1组患者的不良反应总发生率为6.00%,治疗2组患者的不良反应总发生率为10.00%,两组患者的不良反应总发生率比较,差异无统计学意义(P>0.05)。两组患者治疗前的VAS、ADL评分比较,差异无统计学意义(P>0.05),治疗后,治疗1组患者的VAS评分低于治疗2组,ADL评分高于治疗2组,差异均有统计学意义(P<0.05)。结论将胃复春片联合艾司奥美拉唑镁肠溶片治疗应用于脾胃虚弱型十二指肠球部溃疡患者时,不仅安全可靠,且疗效显著,患者腹痛、溃疡消失时间短,此方法值得应用与推广。
Objective To investigate the efficacy of Weifuchun Tablets combined with Esomeprazole Magnesium Enteric-coated Tablets in the treatment of duodenal bulbar ulcer in the spleen and stomach deficiency type. Methods A total of 100 patients with duodenal bulbar ulcer identified as spleen and stomach deficiency pattern who were admitted to our hospital from September 2016 to February 2018 were enrolled in the study. They were equally divided into treatment group 1 and treatment group 2 according to the random number table. In the treatment group 1, WeifuchunTablets combined with Esomeprazole Magnesium Enteric-coated Tablets was used, while in the treatment group 2, Esomeprazole Magnesium Enteric-coated Tablets alone was adopted. The efficacy of treatment, the disappearance time of abdominal pain and ulcer, visual simulation score(VAS), daily living ability(ADL) score and adverse reactions were compared between the two groups. Results The total effectiveness rate of the treatment group 1 was 98.00%, which was higher than that of the treatment group 2 accounting for 86.00% with a statistical difference(P<0.05). The time of abdominal pain and ulcer disappeared in the treatment group 1 was shorter compared with those in the treatment group 2 with statistical significance(P<0.05). The total incidence of adverse reactions was 6.00% in the treatment group and10.00% in the treatment group. There was no statistically significant difference in the total incidence of adverse reactions between the two groups(P>0.05). There was no statistically significant difference between the two groups in VAS and ADL score before treatment(P>0.05). After treatment, the VAS score of treatment group 1 was lower than that of the treatment group 2, and the ADL score was higher than that of the treatment group 2, the differences were statistically significant(P<0.05). Conclusion The application of Weifuchun Tablets combined with Esomeprazole Magnesium Enteric-coated Tablets in the treatment of patients with duodenal bulbar ulcer identified as spleen and stomach deficiency pattern is not only safe and reliable, but also exerts a remarkable curative effect. The disappearance time of patient′s abdominal pain and ulcer is short. It is worthy of application and promotion.
Objective To investigate the efficacy of Weifuchun Tablets combined with Esomeprazole Magnesium Enteric-coated Tablets in the treatment of duodenal bulbar ulcer in the spleen and stomach deficiency type. Methods A total of 100 patients with duodenal bulbar ulcer identified as spleen and stomach deficiency pattern who were admitted to our hospital from September 2016 to February 2018 were enrolled in the study. They were equally divided into treatment group 1 and treatment group 2 according to the random number table. In the treatment group 1, WeifuchunTablets combined with Esomeprazole Magnesium Enteric-coated Tablets was used, while in the treatment group 2, Esomeprazole Magnesium Enteric-coated Tablets alone was adopted. The efficacy of treatment, the disappearance time of abdominal pain and ulcer, visual simulation score(VAS), daily living ability(ADL) score and adverse reactions were compared between the two groups. Results The total effectiveness rate of the treatment group 1 was 98.00%, which was higher than that of the treatment group 2 accounting for 86.00% with a statistical difference(P<0.05). The time of abdominal pain and ulcer disappeared in the treatment group 1 was shorter compared with those in the treatment group 2 with statistical significance(P<0.05). The total incidence of adverse reactions was 6.00% in the treatment group and10.00% in the treatment group. There was no statistically significant difference in the total incidence of adverse reactions between the two groups(P>0.05). There was no statistically significant difference between the two groups in VAS and ADL score before treatment(P>0.05). After treatment, the VAS score of treatment group 1 was lower than that of the treatment group 2, and the ADL score was higher than that of the treatment group 2, the differences were statistically significant(P<0.05). Conclusion The application of Weifuchun Tablets combined with Esomeprazole Magnesium Enteric-coated Tablets in the treatment of patients with duodenal bulbar ulcer identified as spleen and stomach deficiency pattern is not only safe and reliable, but also exerts a remarkable curative effect. The disappearance time of patient′s abdominal pain and ulcer is short. It is worthy of application and promotion.
引文
[1]陈冻伢,曹红艳.慢性胃疾病患者血清胃蛋白酶原水平变化观察及临床意义[J].浙江临床医学,2017,19(4):690-691.
[2]李琳,肖淑萍,周晓颖,等.十二指肠球部溃疡患者38例根除幽门螺杆菌后胃肠道微生物菌群的改变[J].中华消化杂志,2016,36(1):41-43.
[3]Levenstein S,Rosenstock S,Jacobsen RK,et al.Psychological stress increases risk for peptic ulcer,regardless of Helicobacter pylori infection or use of nonsteroidal anti-inflammatory drugs[J].Clin Gastroenterol Hepatol,2015,13(3):498-506.
[4]刘兆辉,范爽,丛靓,等.十二指肠球部溃疡癌变2例报道[J].胃肠病学和肝病学杂志,2018,27(3):359-360.
[5]王经荣,郑梅英.胃铋镁联合三联疗法治疗幽门螺杆菌阳性十二指肠球部溃疡的效果[J].中国医药导报,2015,4(29):112-115.
[6]Alejandra TlO,Torres J,Norma Sánch ez-Zauco,et al.Polymorphisms in TLR9 but not in TLR5 increase the risk for duodenal ulcer and alter cytokine expression in the gastric mucosa[J]. Innate Immunity,2015,21(7):706-713.
[7]刘雅静.自拟健胃愈疡汤联合三联疗法对H.pylori阳性十二指肠球部溃疡患者血浆胃肠激素、胃电图及生活质量的影响[J].现代中西医结合杂志,2016,25(32):3555-3558.
[8]Levenstein S,Rosenstock S,Jacobsen RK,et al.Parameters of proliferation and apoptosis of epithelial cells in the gastric mucosa in indigenous and non-indigenous residents of khakassia with Helicobacter pylori positive duodenal ulcer disease[J].Bull Exp Biol Med,2015,158(4):431-433.
[9]刘艳秋,吴键,佘强等.质子泵抑制剂四联疗法治疗幽门螺杆菌阳性十二指肠球部溃疡的药物经济学评价[J].江苏医药,2017,43(21):1559-1563.
[10]赵静,李建义.奥美拉唑联合铝碳酸镁治疗十二指肠球后溃疡的疗效观察[J].中国基层医药,2015,22(8):1250-1251.
[11]Levenstein,Susan,Rosenstock,Steffen,Jacobsen,Rikke Kart et al.Psychological stress increases risk for peptic ulcer,regardless of Helicobacter pylori infection or use of nonsteroidal anti-inflammatory drugs[J].Clin Gastroenterol Hepatol,2015,13(3):498-506.
[12]苏荣.影响十二指肠球部溃疡患者复发的危险因素分析[J].山西医药杂志,2016,45(11):1316-1319.
[13]苏琴.中西医结合治疗十二指肠溃疡37例临床研究[J].河南中医,2017,37(12):2159-2161.
[14]叶乙,陈丙梁.中西医结合治疗十二指肠溃疡70例[J].长春中医药大学学报,2015,31(1):137-140.
[15]安毅,康伟.健胃愈疡汤联合西药治疗十二指肠球部溃疡的临床疗效及对血浆胃肠激素的影响[J].陕西中医,2016,37(10):1334-1335.
[16]范春梅,乔金婉.胃复春片联合埃索美拉唑治疗老年慢性萎缩性胃炎的效果及对血清炎性因子的影响[J].中国医药导报,2017,14(28):125-128.
[17]伍中久.腹腔镜手术与传统开腹手术治疗胃十二指肠溃疡穿孔的效果研究[J].中国医药科学,2018,8(8):224-226.
[18]王名南,黄德秋,吴少麟,等.慢性胃部病变与血清胃蛋白酶原变化的临床研究[J].中国医药科学,2017,7(9):211-213.
[2]李琳,肖淑萍,周晓颖,等.十二指肠球部溃疡患者38例根除幽门螺杆菌后胃肠道微生物菌群的改变[J].中华消化杂志,2016,36(1):41-43.
[3]Levenstein S,Rosenstock S,Jacobsen RK,et al.Psychological stress increases risk for peptic ulcer,regardless of Helicobacter pylori infection or use of nonsteroidal anti-inflammatory drugs[J].Clin Gastroenterol Hepatol,2015,13(3):498-506.
[4]刘兆辉,范爽,丛靓,等.十二指肠球部溃疡癌变2例报道[J].胃肠病学和肝病学杂志,2018,27(3):359-360.
[5]王经荣,郑梅英.胃铋镁联合三联疗法治疗幽门螺杆菌阳性十二指肠球部溃疡的效果[J].中国医药导报,2015,4(29):112-115.
[6]Alejandra TlO,Torres J,Norma Sánch ez-Zauco,et al.Polymorphisms in TLR9 but not in TLR5 increase the risk for duodenal ulcer and alter cytokine expression in the gastric mucosa[J]. Innate Immunity,2015,21(7):706-713.
[7]刘雅静.自拟健胃愈疡汤联合三联疗法对H.pylori阳性十二指肠球部溃疡患者血浆胃肠激素、胃电图及生活质量的影响[J].现代中西医结合杂志,2016,25(32):3555-3558.
[8]Levenstein S,Rosenstock S,Jacobsen RK,et al.Parameters of proliferation and apoptosis of epithelial cells in the gastric mucosa in indigenous and non-indigenous residents of khakassia with Helicobacter pylori positive duodenal ulcer disease[J].Bull Exp Biol Med,2015,158(4):431-433.
[9]刘艳秋,吴键,佘强等.质子泵抑制剂四联疗法治疗幽门螺杆菌阳性十二指肠球部溃疡的药物经济学评价[J].江苏医药,2017,43(21):1559-1563.
[10]赵静,李建义.奥美拉唑联合铝碳酸镁治疗十二指肠球后溃疡的疗效观察[J].中国基层医药,2015,22(8):1250-1251.
[11]Levenstein,Susan,Rosenstock,Steffen,Jacobsen,Rikke Kart et al.Psychological stress increases risk for peptic ulcer,regardless of Helicobacter pylori infection or use of nonsteroidal anti-inflammatory drugs[J].Clin Gastroenterol Hepatol,2015,13(3):498-506.
[12]苏荣.影响十二指肠球部溃疡患者复发的危险因素分析[J].山西医药杂志,2016,45(11):1316-1319.
[13]苏琴.中西医结合治疗十二指肠溃疡37例临床研究[J].河南中医,2017,37(12):2159-2161.
[14]叶乙,陈丙梁.中西医结合治疗十二指肠溃疡70例[J].长春中医药大学学报,2015,31(1):137-140.
[15]安毅,康伟.健胃愈疡汤联合西药治疗十二指肠球部溃疡的临床疗效及对血浆胃肠激素的影响[J].陕西中医,2016,37(10):1334-1335.
[16]范春梅,乔金婉.胃复春片联合埃索美拉唑治疗老年慢性萎缩性胃炎的效果及对血清炎性因子的影响[J].中国医药导报,2017,14(28):125-128.
[17]伍中久.腹腔镜手术与传统开腹手术治疗胃十二指肠溃疡穿孔的效果研究[J].中国医药科学,2018,8(8):224-226.
[18]王名南,黄德秋,吴少麟,等.慢性胃部病变与血清胃蛋白酶原变化的临床研究[J].中国医药科学,2017,7(9):211-213.